Health
Yale Cancer Center Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers – Yale School of Medicine
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib…
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen…
Continue Reading
-
General22 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
Noosa News19 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News11 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General11 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final